Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

NCT ID: NCT02201602

Last Updated: 2016-09-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2016-07-31

Brief Summary

Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.

Detailed Description

Sulphonylurea (SU) is a glucose-lowering agent used widely to treat type 2 diabetes mellitus (T2DM). SU promotes insulin secretion from the pancreatic islet beta cell via binding and inhibition of the ATP-sensitive potassium (KATP) channel. The KATP channel is made up of two subcomponents, an inner Kir6.2 K+ channel (coded by the KCNJ11 gene) and an outer SU receptor 1 (SUR1) (coded by the ABCC8 gene). Although all SUs are mechanistically similar in terms of increasing insulin secretion, they bind to distinct regions of Kir 6.2 and SUR1 to exert their function. Different types of SU (e.g. tolbutamide, glibenclamide, glipizide, glimepiride and gliclazide) can therefore be grouped by their binding sites (A/B/A+B site) on the KATP channel [3]. Interestingly, the KCNJ11 E23K (rs5219) variant was shown to confer susceptibility to T2DM and the ABCC8 S1369A (rs757110) variant was found to be in complete linkage disequilibrium with it i.e. inherited together as a genetic block (haplotype). A recent in vitro molecular study suggested that the minor haplotype (K23/A1369) of KATP channel is sensitive to inhibition by gliclazide (binds to A-site) but not glibenclamide (binds to A+B site), and that the increased responsiveness to gliclazide was largely due to the A1369 allele. Understanding how the response to these two SUs may vary with the presence of the minor haplotype (K23/A1369) would therefore be beneficial for customization of patient treatment to achieve better clinical outcomes.

Conditions

Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gliclazide

Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks

Group Type: EXPERIMENTAL

Gliclazide

Intervention Type: DRUG

Glibenclamide

Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks

Group Type: ACTIVE_COMPARATOR

Glibenclamide

Intervention Type: DRUG

Interventions

Gliclazide

Intervention Type: DRUG

Glibenclamide

Intervention Type: DRUG

Other Intervention Names

Sun-Glizide; SIN09350P; Benil; SIN07284P

Eligibility Criteria

Inclusion Criteria

• Type 2 diabetes
• Age 21-65
• HbA1c >8.0% on two consecutive visits

Exclusion Criteria

• Currently taking insulin at a regime more complex than basal insulin
• Not willing to perform self-blood glucose monitoring (SBGM)
• Renal impairment i.e. eGFR<50mls/min
• Pregnancy or unwilling to practice adequate contraception
• Taking other medications that may affect blood glucose e.g. systemic glucocorticoids.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Khoo Teck Puat Hospital

OTHER

Sponsor Role: lead

Responsible Party

Su Chi Lim

Senior Consultant

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Su Chi Lim, MBBS, PhD

Role: PRINCIPAL_INVESTIGATOR

Khoo Teck Puat Hospital

Locations

Khoo Teck Puat Hospital

Singapore, Singapore, Singapore

Countries

Singapore

References

Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley AT, Frayling TM. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003 Feb;52(2):568-72. doi: 10.2337/diabetes.52.2.568.

Reference Type: BACKGROUND

PMID: 12540637 (View on PubMed)

Hamming KS, Soliman D, Matemisz LC, Niazi O, Lang Y, Gloyn AL, Light PE. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes. 2009 Oct;58(10):2419-24. doi: 10.2337/db09-0143. Epub 2009 Jul 8.

Reference Type: BACKGROUND

PMID: 19587354 (View on PubMed)

Other Identifiers

Gliclazide

Identifier Type: -

Identifier Source: org_study_id